stockrowSpyre Therapeutics, Inc.
SYRE Healthcare Biotechnology
Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.
- EPS
- −624.8%
- Free cash flow
- −108.8%
Quarter to September 2026, against a year earlier
Follow SYRE
Alert me
Spyre Therapeutics, Inc. (SYRE) EV/EBITDA
Spyre Therapeutics, Inc. has no meaningful EV/EBITDA: its trailing twelve-month EBITDA is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 2.0× (June 2016) — the current reading is the lowest in ten years.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2023 | 0.0× | (94.44%) |
| FY2022 | 0.2× | — |
| FY2021 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.9× | (49.39%) |
| FY2015 | 1.7× | — |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Dec 2023 | 0.0× | (98.50%) |
| Jun 2023 | 0.9× | 523.99% |
| Mar 2023 | 0.1× | (40.75%) |
| Dec 2022 | 0.2× | (15.64%) |
| 19 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| TWST Twist Bioscience Corporation compare | n/m |
| SYRE Spyre Therapeutics, Inc. | n/m |
| CYTK Cytokinetics, Incorporated compare | n/m |
| IBRX ImmunityBio, Inc. compare | n/m |
| MDGL Madrigal Pharmaceuticals, Inc. compare | n/m |
| KRYS Krystal Biotech, Inc. compare | 34.1× |
| CAI Caris Life Sciences,�Inc. compare | 39.4× |
| TGTX TG Therapeutics, Inc. compare | 62.0× |
| PTGX Protagonist Therapeutics, Inc. compare | 145× |
| Biotechnology industry median | 0.7× |
| Healthcare sector median | 8.4× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on SYRE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement